Advertisement

The Complexity of a Respiratory Patient

  • Lowie E. G. W. Vanfleteren
Chapter

Abstract

Although chronic obstructive pulmonary disease (COPD) is defined by the presence of chronic airflow limitation, it is considered a complex, heterogeneous, and multicomponent disease. The heterogeneity and complexity is seen in the pulmonary expression of the disease, ranging from chronic bronchitis without emphysema to emphysema without bronchitis, in the presence or absence of exacerbations, in the differential diagnosis with asthma, but also in comorbidities and extrapulmonary manifestations, which have important contributions to disease expression, disease burden, and survival.

References

  1. 1.
    Agusti A, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res. 2010;11:122.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Vestbo J, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347–65.CrossRefPubMedGoogle Scholar
  3. 3.
    From the global strategy for the diagnosis, management and prevention of COPD, global initiative for chronic obstructive lung disease (GOLD) 2017. http://goldcopd.org.
  4. 4.
    Han MK, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med. 2010;182(5):598–604.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Agusti A. The path to personalised medicine in COPD. Thorax. 2014;69(9):857–64.CrossRefPubMedGoogle Scholar
  6. 6.
    Martinez FJ, et al. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet. 2015;385(9971):857–66.CrossRefPubMedGoogle Scholar
  7. 7.
    Uzun S, et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2014;2(5):361–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Miravitlles M, et al. Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review. Respir Res. 2016;17(1):112.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Fishman A, et al. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med. 2003;348(21):2059–73.CrossRefPubMedGoogle Scholar
  10. 10.
    Shah PL, et al. Lung volume reduction for emphysema. Lancet Respir Med. 2016;Google Scholar
  11. 11.
    Postma DS, Rabe KF. The asthma-COPD overlap syndrome. N Engl J Med. 2015;373(13):1241–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Pascoe S, et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med. 2015;3(6):435–42.CrossRefPubMedGoogle Scholar
  13. 13.
  14. 14.
    Vanfleteren LE, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187(7):728–35.CrossRefPubMedGoogle Scholar
  15. 15.
    Clini EM, Beghe B, Fabbri LM. Chronic obstructive pulmonary disease is just one component of the complex multimorbidities in patients with COPD. Am J Respir Crit Care Med. 2013;187(7):668–71.CrossRefPubMedGoogle Scholar
  16. 16.
    Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome? Lancet. 2007;370(9589):797–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Gan WQ, et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004;59(7):574–80.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Vanfleteren LE, et al. Arterial stiffness in patients with COPD: the role of systemic inflammation and the effects of pulmonary rehabilitation. Eur Respir J. 2014;43(5):1306–15.CrossRefPubMedGoogle Scholar
  19. 19.
    Agusti A, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One. 2012;7(5):e37483.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Sinden NJ, Stockley RA. Systemic inflammation and comorbidity in COPD: a result of ‘overspill’ of inflammatory mediators from the lungs? Review of the evidence. Thorax. 2010;65(10):930–6.CrossRefPubMedGoogle Scholar
  21. 21.
    Breyer MK, et al. Highly elevated C-reactive protein levels in obese patients with COPD: a fat chance? Clin Nutr. 2009;28(6):642–7.CrossRefPubMedGoogle Scholar
  22. 22.
    Mannino DM, et al. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008;32(4):962–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Divo M, et al. Comorbidities and risk of mortality in patients with COPD. Am J Respir Crit Care Med. 2012;186(2):155–61.CrossRefPubMedGoogle Scholar
  24. 24.
    Vanfleteren LE, et al. Frequency and relevance of ischemic electrocardiographic findings in patients with chronic obstructive pulmonary disease. Am J Cardiol. 2011;108(11):1669–74.CrossRefPubMedGoogle Scholar
  25. 25.
    Lange P, et al. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. Am J Respir Crit Care Med. 2012;186(10):975–81.CrossRefPubMedGoogle Scholar
  26. 26.
    Agusti A, et al. Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. Eur Respir J. 2013;42(3):636–46.CrossRefPubMedGoogle Scholar
  27. 27.
    Agusti A, et al. FAQs about the GOLD 2011 assessment proposal of COPD: a comparative analysis of four different cohorts. Eur Respir J. 2013;42(5):1391–401.CrossRefPubMedGoogle Scholar
  28. 28.
    Wouters EF. COPD: a chronic and overlooked pulmonary disease. Lancet. 2007;370(9589):715–6.CrossRefPubMedGoogle Scholar
  29. 29.
    Maddocks M, et al. Physical frailty and pulmonary rehabilitation in COPD: a prospective cohort study. Thorax. 2016;Google Scholar
  30. 30.
    Boyd CM, et al. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA. 2005;294(6):716–24.CrossRefPubMedGoogle Scholar
  31. 31.
    Doos L, et al. Multi-drug therapy in chronic condition multimorbidity: a systematic review. Fam Pract. 2014;31(6):654–63.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.CIRO, A Centre of Expertise for Chronic Organ FailureHornThe Netherlands
  2. 2.Respiratory DepartmentMaastricht University Medical CentreMaastrichtThe Netherlands

Personalised recommendations